In this podcast, Dr. Emmanuel Antonarakis discusses his novel clinical trial evaluating PARP inhibitors in high-risk and biochemically recurrent prostate cancer.
Emmanuel Antonarakis, MD
Advertisement
Articles by Emmanuel Antonarakis, MD
Advertisement
Latest Updated Articles
Synthetic Lethality of PARP Inhibitors in Prostate CancerPublished: May 3rd 2018 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Sac-TMT Combo Produces Encouraging Activity in Pretreated Metastatic CRPC
2
Molecular Insights Into Cancer Cachexia: An Evolution in Identifying the Syndrome
3
FDA Grants Interchangeability Designation to 2 Denosumab Biosimilars
4
Zurletrectinib Generates Responses in Advanced NTRK Fusion Solid Tumors
5
